CD33 Targeted Therapies
1 drugsAbout CD33
CD33, or Siglec-3, is a transmembrane receptor on myeloid cells like monocytes and granulocytes. It participates in cell-cell interactions and immune regulation as a cell surface marker.
CD33's expression on myeloid lineage cells makes it a therapeutic target, especially in oncology. However, there is currently no genetic evidence directly linking CD33 to specific diseases.
CD33 is targeted by one FDA-approved antibody-drug conjugate, MYLOTARG (gemtuzumab ozogamicin), for acute myeloid leukemia. Pfizer is the sole company with an approved CD33-targeting drug.
Top CD33 Drugs
Pfizer is the only company with an approved drug targeting CD33.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's validation.
CD33 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CD33, using adc modality.
Explore alternative modalities like bispecifics or CAR-T therapies to differentiate from existing ADCs.
CD33 Clinical Trials 47 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CD33. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 9 | 4 | 2 | 69% |
| Phase 2 | 25 | 10 | 4 | 11 | 71% |
| Phase 3 | 6 | 1 | 1 | 4 | 50% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CD33 Drug Approval Timeline (2017 - 2017)
The first and only drug, MYLOTARG, was approved in 2017.
The approval timeline indicates potential saturation; new therapies must demonstrate significant advantages.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 35 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CD33. A trial counts if an approved drug acting on CD33 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.